Table 4.
RCTs evaluating PCI-related OS in NSCLC.
| Study | Median follow-up in months | Median OS in months (PCI vs no PCI) | p-Value |
|---|---|---|---|
| VALG | Not reported | Not reported | Not reported |
| MDACC | 13.6 (PCI), 12.7 (no PCI) | 60.3 vs 56.3 | Not significant |
| RTOG 8403 | Not reported | 8.4 vs 8.3 | 0.36 |
| SWOG | Not reported | 8.0 vs 11.0 | Significant |
| RTOG 0214 | 23.8 | 25.8 vs 24.8 | 0.86 |
| Li | 68.1 (PCI), 65.2 (no PCI) | 31.2 vs 27.4 | 0.31 |
| NVALT-11 | 53.3 | 24.2 vs 21.9 | 0.56 |
OS, overall survival; PCI, prophylactic cranial irradiation; NSCLC, non-small cell lung cancer; RCTs, randomized controlled trials.